B-intervention	0	8	Exercise
O	9	11	as
O	12	13	a
O	14	24	diagnostic
O	25	28	and
O	29	40	therapeutic
O	41	45	tool
O	46	49	for
O	50	60	preventing
B-condition	61	75	cardiovascular
I-condition	76	85	morbidity
O	86	88	in
O	89	95	breast
O	96	102	cancer
O	103	111	patients
O	111	112	-
O	113	116	the
O	117	123	BReast
O	124	130	cancer
O	131	139	EXercise
O	140	152	InTervention
O	153	154	(
O	154	160	BREXIT
O	160	161	)
O	162	167	trial
O	168	176	protocol
O	176	177	.

O	178	191	Anthracycline
O	192	204	chemotherapy
O	205	206	(
O	206	208	AC
O	208	209	)
O	210	212	is
O	213	215	an
O	216	227	efficacious
O	228	229	(
O	229	232	neo
O	232	233	)
O	234	242	adjuvant
O	243	252	treatment
O	253	256	for
O	257	262	early
O	262	263	-
O	263	268	stage
O	269	275	breast
O	276	282	cancer
O	283	284	(
O	284	287	BCa
O	287	288	)
O	288	289	,
O	290	293	but
O	294	296	is
O	297	307	associated
O	308	312	with
O	313	315	an
O	316	325	increased
O	326	330	risk
O	331	333	of
O	334	341	cardiac
O	342	353	dysfunction
O	354	357	and
O	358	368	functional
O	369	379	disability
O	379	380	.

O	381	393	Observations
O	394	401	suggest
O	402	406	that
O	407	414	regular
O	415	423	exercise
O	424	427	may
O	428	430	be
O	431	432	a
O	433	439	useful
O	440	447	therapy
O	448	451	for
O	452	455	the
O	456	466	prevention
O	467	469	of
O	470	484	cardiovascular
O	485	494	morbidity
O	495	498	but
O	499	501	it
O	502	504	is
O	505	508	yet
O	509	511	to
O	512	514	be
O	515	527	interrogated
O	528	530	in
O	531	532	a
O	533	538	large
O	539	549	randomised
O	550	555	trial
O	555	556	.

O	557	560	The
O	561	568	primary
O	569	573	aims
O	574	576	of
O	577	581	this
O	582	587	study
O	588	591	are
O	592	594	to
O	594	595	:
O	596	597	1
O	597	598	)
O	599	608	determine
O	609	611	if
O	612	614	12
O	614	615	-
O	615	621	months
O	622	624	of
O	625	627	ET
O	628	637	commenced
O	638	640	at
O	641	644	the
O	645	650	onset
O	651	653	of
O	654	656	AC
O	657	660	can
O	661	667	reduce
O	668	671	the
O	672	682	proportion
O	683	685	of
O	686	689	BCa
O	690	698	patients
O	699	703	with
O	704	714	functional
O	715	725	disability
O	726	727	(
O	727	731	peak
O	732	735	VO2
O	735	736	,
O	737	738	<
O	739	741	18
O	742	744	ml
O	744	745	/
O	745	747	kg
O	747	748	/
O	748	751	min
O	751	752	)
O	752	753	,
O	754	757	and
O	758	759	2
O	759	760	)
O	761	768	compare
O	769	776	current
O	777	785	standard
O	785	786	-
O	786	788	of
O	788	789	-
O	789	793	care
O	794	797	for
O	798	807	detecting
O	808	815	cardiac
O	816	827	dysfunction
O	828	829	(
O	829	836	resting
O	837	841	left
O	841	842	-
O	842	853	ventricular
O	854	862	ejection
O	863	871	fraction
O	872	880	assessed
O	881	885	from
O	886	887	3
O	887	888	-
O	888	899	dimensional
O	900	916	echocardiography
O	916	917	)
O	918	920	to
O	921	929	measures
O	930	932	of
O	933	940	cardiac
O	941	948	reserve
O	949	950	(
O	950	954	peak
O	955	963	exercise
O	964	971	cardiac
O	972	978	output
O	979	987	assessed
O	988	992	from
O	993	1001	exercise
O	1002	1009	cardiac
O	1010	1018	magnetic
O	1019	1028	resonance
O	1029	1036	imaging
O	1036	1037	)
O	1038	1041	for
O	1042	1052	predicting
O	1053	1056	the
O	1057	1068	development
O	1069	1071	of
O	1072	1082	functional
O	1083	1093	disability
O	1094	1096	12
O	1096	1097	-
O	1097	1103	months
O	1104	1113	following
O	1114	1116	AC
O	1116	1117	.

O	1118	1127	Secondary
O	1128	1132	aims
O	1133	1136	are
O	1137	1139	to
O	1140	1146	assess
O	1147	1150	the
O	1151	1158	effects
O	1159	1161	of
O	1162	1164	ET
O	1165	1167	on
O	1168	1175	VO2peak
O	1175	1176	,
O	1177	1181	left
O	1182	1193	ventricular
O	1194	1204	morphology
O	1204	1205	,
O	1206	1214	vascular
O	1215	1224	stiffness
O	1224	1225	,
O	1226	1233	cardiac
O	1234	1244	biomarkers
O	1244	1245	,
O	1246	1250	body
O	1251	1262	composition
O	1262	1263	,
O	1264	1268	bone
O	1269	1276	mineral
O	1277	1284	density
O	1284	1285	,
O	1286	1292	muscle
O	1293	1301	strength
O	1301	1302	,
O	1303	1311	physical
O	1312	1320	function
O	1320	1321	,
O	1322	1330	habitual
O	1331	1339	physical
O	1340	1348	activity
O	1348	1349	,
O	1350	1359	cognitive
O	1360	1368	function
O	1368	1369	,
O	1370	1373	and
O	1374	1390	multidimensional
O	1391	1398	quality
O	1399	1401	of
O	1402	1406	life
O	1406	1407	.

B-total-participants	1408	1411	One
I-total-participants	1412	1419	hundred
B-eligibility	1420	1425	women
I-eligibility	1426	1430	with
I-eligibility	1431	1436	early
I-eligibility	1436	1437	-
I-eligibility	1437	1442	stage
I-eligibility	1443	1446	BCa
I-eligibility	1447	1448	(
I-eligibility	1448	1450	40
I-eligibility	1450	1451	-
I-eligibility	1451	1453	75
I-eligibility	1454	1459	years
I-eligibility	1459	1460	)
I-eligibility	1461	1470	scheduled
I-eligibility	1471	1474	for
I-eligibility	1475	1477	AC
O	1478	1482	will
O	1483	1485	be
O	1486	1496	randomized
O	1497	1499	to
O	1500	1502	12
O	1502	1503	-
O	1503	1509	months
O	1510	1512	of
O	1513	1523	structured
O	1524	1532	exercise
O	1533	1541	training
O	1542	1543	(
O	1543	1544	n
O	1545	1546	=
B-intervention-participants	1547	1549	50
O	1549	1550	)
O	1551	1553	or
O	1554	1555	a
B-control	1556	1561	usual
I-control	1562	1566	care
I-control	1567	1574	control
I-control	1575	1580	group
O	1581	1582	(
O	1582	1583	n
O	1584	1585	=
B-control-participants	1586	1588	50
O	1588	1589	)
O	1589	1590	.

O	1591	1603	Participants
O	1604	1608	will
O	1609	1611	be
O	1612	1620	assessed
O	1621	1623	at
O	1624	1632	baseline
O	1632	1633	,
O	1634	1635	4
O	1635	1636	-
O	1636	1641	weeks
O	1642	1651	following
O	1652	1662	completion
O	1663	1665	of
O	1666	1668	AC
O	1669	1670	(
O	1670	1671	4
O	1671	1672	-
O	1672	1678	months
O	1678	1679	)
O	1680	1683	and
O	1684	1686	at
O	1687	1689	12
O	1689	1690	-
O	1690	1696	months
O	1697	1700	for
O	1701	1704	all
O	1705	1713	measures
O	1713	1714	.

O	1715	1720	Women
O	1721	1730	diagnosed
O	1731	1735	with
O	1736	1741	early
O	1741	1742	-
O	1742	1747	stage
O	1748	1751	BCa
O	1752	1756	have
O	1757	1766	increased
O	1767	1774	cardiac
O	1775	1784	mortality
O	1784	1785	.

O	1786	1790	More
O	1791	1800	sensitive
O	1801	1811	strategies
O	1812	1815	for
O	1816	1826	diagnosing
O	1827	1830	and
O	1831	1841	preventing
O	1842	1844	AC
O	1844	1845	-
O	1845	1852	induced
O	1853	1867	cardiovascular
O	1868	1878	impairment
O	1879	1882	are
O	1883	1891	critical
O	1892	1895	for
O	1896	1904	reducing
O	1905	1919	cardiovascular
O	1920	1929	morbidity
O	1930	1933	and
O	1934	1943	improving
O	1944	1948	long
O	1948	1949	-
O	1949	1953	term
O	1954	1960	health
O	1961	1969	outcomes
O	1970	1972	in
O	1973	1976	BCa
O	1977	1986	survivors
O	1986	1987	.

O	1988	1997	Australia
O	1998	1999	&
O	2000	2003	New
O	2004	2011	Zealand
O	2012	2020	Clinical
O	2021	2027	Trials
O	2028	2036	Registry
O	2037	2038	(
O	2038	2044	ANZCTR
O	2044	2045	)
O	2045	2046	,
O	2047	2049	ID
O	2049	2050	:
O	2051	2065	12617001408370
O	2066	2067	.

O	2068	2078	Registered
O	2079	2081	on
O	2082	2085	5th
O	2086	2088	of
O	2089	2096	October
O	2097	2101	2017
O	2101	2102	.
